METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
申请人:Novartis AG
公开号:US20210387995A1
公开(公告)日:2021-12-16
The present disclosure provides for a compound according to formula (I)
or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
Carbene Bridging C-H Activation: Facile Isocoumarin Synthesis Through Palladium-Catalyzed Reaction of 2-Pseudohalobenzaldehydes with Aryl Diazoesters
作者:Chao Yan、Yinghua Yu、Bo Peng、Xueliang Huang
DOI:10.1002/ejoc.201901738
日期:2020.2.14
A strategy based on carbene bridging C–H activation is described. The bridging arm is generated via migratory insertion of a palladium carbene intermediate. Through this distinct pathway, a variety of isocoumarins could be prepared in a modular manner.
Direct and selective synthesis of 3-arylphthalides via nickel-catalyzed aryl addition/intramolecular esterification
作者:Qing Qiang、Feipeng Liu、Zi-Qiang Rong
DOI:10.1016/j.tet.2021.132162
日期:2021.6
Herein we report a nickel-catalyzed aryl addition/intramolecular esterification in a cascade fashion. Under the combination of commercially available nickel precursor and tridentate ligand, the one pot protocol offers a direct, simple and regioselective approach to access 3-aryl phthalide derivatives from two readily available substrates with good efficiency, broad scope as well as satisfactory functional
Compounds with a pyridoisoquinolinone core often appear as members of the protoberberine alkaloid family. Traditional methods to construct this framework normally rely on manipulation of sophisticated reactants. Herein, a palladium-catalyzed reaction of readily available pyridotriazoles and o-bromo/pseudohalo benzaldehydes is described, which provides a modular approach to pyridoisoquinolinone derivatives
[EN] METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4- B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS<br/>[FR] COMPOSÉS DE MÉTHYL 2-MÉTHYL-5-OXO-1,4,5,7-TÉTRADHYDRO-FURO[3,4-B]PYRIDINE-3-CARBOXYLATE DE MÉTHYLE UTILISÉS EN TANT QU'ACTIVATEURS DE CAV1.2
申请人:NOVARTIS AG
公开号:WO2021255608A1
公开(公告)日:2021-12-23
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.